Physician profile
Gary W Olson
NPI 1861426983
$11,516.03
in general payments reported to CMS, 2019-2025
39 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,272 · 2020: $1,111 · 2021: $2,290 · 2022: $2,661 · 2023: $2,303 · 2024: $612 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,884.43 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,457.91 | 2019-2024 | |
| Amgen INC. | $1,242.92 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,046.40 | 2019-2024 | Farxiga, Wainua, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $715.21 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $592.21 | 2019-2023 | Watchman Access System |
| Pfizer INC. | $523.94 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $483.02 | 2019-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $405.07 | 2021-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $276.85 | 2021-2023 | Verquvo |
| Medtronic Vascular, INC. | $243.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.11 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $184.33 | 2021-2025 | |
| Amarin Pharma, INC. | $124.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $120.06 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $113.73 | 2021-2024 | Cardiomems, Gallant |
| Sanofi-Aventis U.S. LLC | $101.97 | 2019 | |
| Medtronic, INC. | $75.89 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Atricure, INC. | $72.59 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $65.14 | 2019-2022 | |
| Cardiva Medical, INC. | $53.67 | 2021-2022 | |
| Irhythm Technologies, INC. | $49.43 | 2022-2023 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $46.84 | 2023 | Inpefa |
| United Therapeutics Corporation | $45.90 | 2019 | |
| Siemens Medical Solutions USA, INC. | $43.79 | 2023-2024 | Artis Icono Floor |
| Portola Pharmaceuticals, LLC | $40.81 | 2019-2020 | |
| Inari Medical, INC. | $35.06 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $32.55 | 2023-2024 | Opsumit, Uptravi |
| Cardiovascular Systems INC. | $32.35 | 2019 | |
| Cvrx, INC. | $31.34 | 2025 | Barostim Neo System |
| Shockwave Medical, INC | $29.92 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $28.18 | 2022 | |
| Astellas Pharma US INC | $20.79 | 2019 | |
| Medicomp INC | $20.48 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.26 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $19.47 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $16.61 | 2023 | Injectafer |
| Molnlycke Health Care US, LLC | $16.29 | 2023 | Mepilex Border Post-Op Ag, Exufiber Ag+, Mepilex Border Sacrum |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.